The invention relates to an organic molecule having a structure of the formula I

##STR00001##

where X=CN or CF.sub.3; D=chemical unit having a structure of the formula I-1:

##STR00002##

where #=attachment point of the unit of formula I-1 to the central phenyl ring in the structure of formula I; A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z; Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

The invention relates to an organic molecule having a structure of the formula I

##STR00001##

where X=CN or CF.sub.3; D=chemical unit having a structure of the formula I-1:

##STR00002##

where #=attachment point of the unit of formula I-1 to the central phenyl ring in the structure of formula I; A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z; Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

The near infrared absorbing curable composition includes: a compound represented by Formula (1); and a compound having a crosslinking group. In Formula (1), X.sup.1 and X.sup.2 each independently represent O, S, or a dicyanomethylene group, and A and B each independently represent a group represented by Formula (2). In Formula (2), a wave line represents a binding site of Formula (1), Y.sub.S represents a group having active hydrogen, A1 represents an aromatic hydrocarbon ring or an aromatic heterocycle, R.sub.Z represents a substituent, m1 represents an integer of 0 to mA, mA represents an integer representing the maximum number of R.sub.Z's which may be substituted in A1, Y.sub.S may be bonded to A1 or R.sub.Z to form a ring, and R.sub.Z may be bonded to A1 to form a ring.

##STR00001##

The invention relates to an organic molecule having precisely two units of formula I linked to one another via a single bond or a bridge Y

##STR00001##

where
Y=a divalent group;
X=at each occurrence identically or differently CN and CF.sub.3;
D=chemical unit having a structure of the formula I-1:

##STR00002##

where
#=attachment point of the unit of formula I-1 to the structure of formula I;
A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z;
Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

The invention relates to an organic molecule having precisely two units of formula I linked to one another via a single bond or a bridge Y

##STR00001##

where
Y=a divalent group;
X=at each occurrence identically or differently CN and CF.sub.3;
D=chemical unit having a structure of the formula I-1:

##STR00002##

where
#=attachment point of the unit of formula I-1 to the structure of formula I;
A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z;
Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group, n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group. ##STR00001##

The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group, n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##

A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.

A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.